The $150m venture financing of EDDA Technology was the medical devices industry’s top cross border venture financing deal as total deals worth $973.2m were announced globally in April 2021, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 57.8% over the previous month of $616.93m and a rise of 126.4% when compared with the last 12-month average, which stood at $429.85m.
Comparing cross border venture financing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $526.02m. At the country level, the US topped the list in terms of deal value at $514.5m.
In terms of volumes, North America emerged as the top region for medical devices industry cross border venture financing deals globally, followed by Europe and then Asia-Pacific.
The top country in terms of cross border venture financing deals activity in April 2021 was the US with 11 deals, followed by the China with three and France with two.
In 2021, as of April, medical devices cross border venture financing deals worth $2.15bn were announced globally, marking an increase of 54.7% year on year.
medical devices industry cross border venture financing deals in April 2021: Top deals
The top five medical devices industry cross border venture financing deals accounted for 57.6% of the overall value during April 2021.
The combined value of the top five medical devices cross border venture financing deals stood at $561m, against the overall value of $973.2m recorded for the month.
The top five medical devices industry cross border venture financing deals of April 2021 tracked by GlobalData were:
1) 3W Partners, Orbimed Advisors and SoftBank Vision Fund II’s $150m venture financing of EDDA Technology
2) The $115m venture financing of CeQur by Credit Suisse Entrepreneur Capital, Endeavour Vision, Federated Hermes Kaufmann Fund, GMS Capital, Kingdon Capital Management, SchroderBank AG, Tandem Diabetes Care, VI Partners and Ypsomed
3) Arno Capital, Intel Capital, IPF Management, Lauxera Capital Partners, Optum Ventures, PFM Health Sciences, Relyens, Rezayat Investments, Surgical.ai and Vesalius Biocapital III Partners’ $100m venture financing of Caresyntax
4) The $100m venture financing of Sera Prognostics by aMoon Partners, Anthem, Blue Ox Healthcare Partners SP, Parian Global Management and Vivo Capital
5) Accelmed Partners, Ceros, OurCrowd and Peregrine Ventures’ venture financing of Memic Medical for $96m.
Verdict deals analysis methodology
This analysis considers only announced and completed cross border deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.